The phase I/II clinical trial will investigate whether a combination of E02401 and an immune checkpoint inhibitor can serve as a treatment for progressive or first recurrent glioblastoma multiforme (GBM), an aggressive form of brain cancer. It will evaluate the candidate's safety, tolerability, immunogenicity, and preliminary efficacy in 32 patients with GBM.

Neuro-oncology researcher Wolfgang Wick, PhD, from Heidelberg University Hospital in Germany, will serve as principal investigator for the open-label trial. Patients will be treated at 10 sites in the U.S. and Europe, with the first results expected in 2022.

Immunotherapy candidate E02401 is derived from Enterome's microbiome-derived peptide antigens known as OncoMimics. The novel candidate combines three OncoMimics found in glioblastoma and other aggressive cancers, the company noted.

SAB begins seasonal flu immunotherapy clinical trial
SAB Biotherapeutics has begun a phase I clinical trial evaluating SAB-176 for the treatment of seasonal influenza.

Cancer research groups partner for liquid biopsy trial
The Cancer Research Institute and the Mark Foundation for Cancer Research have partnered on a clinical trial to evaluate whether a novel liquid biopsy...

Grifols delivers COVID-19 immunotherapy for clinical trials
Grifols has delivered the first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials, which will be conducted this summer.

Carisma advances macrophage immunotherapy
Carisma Therapeutics' engineered macrophage immunotherapy has cleared an investigational new drug application through the U.S. Food and Drug Administration....

Immunic begins phase II trial of COVID-19 immunotherapy
Immunic has enrolled the first patients in a phase II clinical trial of IMU-838, a selective oral dihydroorotate dehydrogenase inhibitor, in combination...